TRAIL-DISC formation is androgen-dependent in the human prostatic carcinoma cell line LNCaP

被引:23
作者
Rokhlin, OW
Taghiyev, AF
Guseva, NV
Glover, RA
Syrbu, SI
Cohen, MB
机构
[1] Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA
[2] Univ Iowa, Dept Urol, Iowa City, IA 52242 USA
[3] Univ Iowa, Dept Epidemiol, Iowa City, IA 52242 USA
基金
美国国家卫生研究院;
关键词
TRAIL; prostatic neoplasms; androgen; PI3K/Akt; apoptosis;
D O I
10.4161/cbt.311
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We and others have previously described that the androgen-responsive human prostatic carcinoma cell line LNCaP is resistant to TRAIL and that TRAIL-mediated apoptosis in LNCaP is PI3K/Akt-dependent. In this study, we found that LNCaP remained resistant to treatment with TRAIL after androgen deprivation even in the presence of the PI3K/Akt pathway inhibitor wortmannin. This resistance was determined by failure to form the TRAIL-DISC and by decreased TRAIL-R1 and TRAIL-R2 levels after androgen deprivation; the capacity of TRAIL to induce DISC formation was completely restored in the presence of DHT. TRAIL and wortmannin together accelerated processing of caspase-8 on the DISC and apparently the release of caspase-8 from the DISC into the cytoplasm. Surprisingly, we found that wortmannin decreased the total amount of TRAIL-R1, but not TRAIL-R2, in the cells as well as the amount of TRAIL-R1 precipitated by TRAIL. Our data suggest that TRAIL-DISC formation and sensitivity to TRAIL treatment are androgen-dependent in LNCaP.
引用
收藏
页码:631 / 637
页数:7
相关论文
共 34 条
[1]   Targeting death and decoy receptors of the tumour-necrosis factor superfamily [J].
Ashkenazi, A .
NATURE REVIEWS CANCER, 2002, 2 (06) :420-430
[2]   Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer [J].
Chen, XF ;
Thakkar, H ;
Tyan, F ;
Gim, S ;
Robinson, H ;
Lee, C ;
Pandey, SK ;
Nwokorie, C ;
Onwudiwe, N ;
Srivastava, RK .
ONCOGENE, 2001, 20 (42) :6073-6083
[3]   Restricted localization of the TNF receptor CD120a to lipid rafts: A novel role for the death domain [J].
Cottin, V ;
Doan, JES ;
Riches, DWH .
JOURNAL OF IMMUNOLOGY, 2002, 168 (08) :4095-4102
[4]   A history of prostate cancer treatment [J].
Denmeade, SR ;
Isaacs, JT .
NATURE REVIEWS CANCER, 2002, 2 (05) :389-396
[5]   Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling [J].
El-Deiry, WS .
CELL DEATH AND DIFFERENTIATION, 2001, 8 (11) :1066-1075
[6]   Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/apo-2 ligand gene induces tumor cell apoptosis [J].
Griffith, TS ;
Anderson, RD ;
Davidson, BL ;
Williams, RD ;
Ratliff, TL .
JOURNAL OF IMMUNOLOGY, 2000, 165 (05) :2886-2894
[7]  
Griffith TS, 1999, J IMMUNOL, V162, P2597
[8]   Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5 [J].
Kischkel, FC ;
Lawrence, DA ;
Chuntharapai, A ;
Schow, P ;
Kim, KJ ;
Ashkenazi, A .
IMMUNITY, 2000, 12 (06) :611-620
[9]   Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor [J].
Lin, HK ;
Yeh, SY ;
Kang, HY ;
Chang, CS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (13) :7200-7205
[10]  
Lin JQ, 1999, CANCER RES, V59, P2891